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Abstract 
Spasticity is considered an important neural contributor to muscle hypertonia in children with 
cerebral palsy (CP). It is most often treated with anti-spasticity medication, such as Botulinum Toxin-
A. However, treatment response is highly variable. Part of this variability may be due to the inability 
of clinical tests to differentiate between the neural (e.g. spasticity) and non-neural (e.g. soft tissue 
properties) contributions to hypertonia, leading to the terms ‘spasticity’ and ‘hypertonia’ often being 
used interchangeably. Recent advancements in instrumented spasticity assessments offer objective 
measurement methods for distinction and quantification of hypertonia components. These methods 
can be applied in clinical settings and their results used to fine-tune and improve treatment. We 
reviewed current advancements and new insights with respect to quantifying spasticity and its 
contribution to muscle hypertonia in children with CP. First, we revisit what is known about spasticity 
in children with CP, including the various definitions and its pathophysiology. Second, we summarize 
the state-of-the-art on instrumented spasticity assessment in CP and review the parameters 
developed to quantify the neural and non-neural components of hypertonia. Lastly, the impact these 
quantitative parameters make on clinical decision-making is considered and recommendations for 
future clinical and research investigations are discussed. 
 
Introduction 
Muscle tone regulation helps to maintain normal posture and to facilitate movement [1]. When a 
muscle stretches, the neuromuscular system may respond by automatically altering muscle tone. 
This modulation of the stretch reflex is important in the control of motion and balance maintenance 
[2]. Spasticity is manifested by increased stretch reflex which is intensified with movement velocity 
[3]. This results in excessive and inappropriate muscle activation which can contribute to muscle 
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hypertonia. Spasticity is a known impairment following an upper motor neuron (UMN) lesion, such as 
cerebral palsy (CP). In CP, spasticity is often regarded to be the most common motor impairment [4]. 
However, there are many uncertainties regarding the contribution of spasticity to hypertonia and in 
particular, its contribution to the gait abnormalities seen in CP. 
Much of this uncertainty is related to the miscommunication regarding the definition and 
assessment of spasticity. In clinical terms, hypertonia is assessed as the ‘resistance to passive stretch 
while the patient maintains a relaxed state of muscle activity’ [5]. With spasticity related hypertonia, 
lack of modulation of the stretch reflex causes premature and/or exaggerated muscle contraction that 
may resist the passive stretch. During clinical assessments, different stretch velocities can be 
incorporated and the increase in stretch reflex due to velocity is thereby subjectively evaluated. In 
reality, this clinical interpretation oversimplifies the fundamental physiological mechanisms of 
spasticity. Firstly, it is dependent on the reliance of the subjective interpretation of an examiner; 
secondly, the velocity of the stretch and level of relaxation of the muscle are uncontrolled; and thirdly, 
it does not allow differentiating between the contributions of neural and non-neural components to 
the overall resistance felt while stretching the muscle [6]. Non-neural mechanical muscle properties 
such as stiffness and viscosity are often altered in children with CP [7] and can also contribute to the 
feeling of increased resistance to passive motion (Figure 1). 
 
 
 
Instrumented spasticity assessments are clearly more objective and valid than the clinical spasticity 
scales, but have mostly been developed for adults and have received less attention in children with CP 
[8, 9]. Continued subjective evaluations of hypertonia in children with CP can lead to inaccurate 
management and ignorance of the necessity to distinguish between neural and non-neural 
components. For example, if spasticity contributes more to joint resistance than muscle stiffness, anti-
spasticity medication is required, while in case of predominance of stiffness over spasticity, options 
such as casting and orthotic management are more likely to be effective. Moreover, objective 
measurements allow for improved standardization between different assessors and clinical centers 
Neural related 
e.g. spasticity 
Non-neural related 
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Figure 1. Neural and non-neural mechanisms contributing to increased resistance to passive motion 
in an upper motor neuron syndrome 
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and increase the discrimination power between patients, providing better means to evaluate and 
direct treatment. 
In this review article we firstly revisit what is known about spasticity in CP, its definitions and its 
pathophysiology. Second, we summarize the state-of-the-art on instrumented spasticity assessment 
in this population and review the parameters developed to quantify its contribution to muscle 
hypertonia. Third, we consider the impact of quantification of these parameters on clinical decision 
making and discuss recommendations for future clinical and research investigations. 
 
Cerebral palsy and spasticity 
Three main sub-types of CP are based on the main motor disorder: spastic, dyskinetic, and ataxic 
[4]. All forms are characterized by abnormal posture or movement. In addition, spastic CP, known as 
a pyramidal motor disorder [5], is also characterized by hypertonia, and/or pathological reflex 
activation [4]. In contrast, dyskinetic and ataxic forms of CP are thought to mostly arise from damage 
to the basal ganglia and cerebellum respectively and cause different movement abnormalities. 
Spastic CP is the most commonly diagnosed disorder among children with CP [4]. Spasticity can 
affect the entire body, but is generally worse in the lower limbs of children with bilateral 
involvement, and in the upper limbs of children with unilateral involvement [10]. Spasticity of the 
trunk muscles can cause postural problems while spasticity of bulbar origin can result in difficulty in 
feeding and communication [11]. The most commonly affected lower limb muscles in children with 
CP are gastroc-soleus, hamstrings, rectus femoris, adductors, and psoas. In the upper limb, spasticity 
is most frequently found in the shoulder external rotators, elbow, wrist and finger flexors, and the 
elbow pronators [12]. Spasticity is thought to interfere with voluntary control and to increase energy 
consumption during movement [13]. Additionally, it hampers normal muscle lengthening during 
growth and is thus thought to contribute to the development of secondary muscle and soft tissue 
contractures and to skeletal deformation [14]. Muscle contractures and skeletal deformations can 
result in distorted internal and/or external lever arms resulting in abnormal joint moments during 
gait (lever-arm dysfunctions) [13]. 
 
Spasticity definitions 
There has been much debate regarding the definition of spasticity. This has mostly been due to 
the term being used to refer to a general motor disorder rather than to a specific entity. The 
definition of spasticity by Lance (1980) as ‘a velocity dependent increase in stretch reflex’ [3] gained 
popularity as it provided a specific pathophysiological rationale while acknowledging that spasticity 
was only one of the many features of an UMN syndrome. Other proprioceptive, cutaneous [15], and 
nociceptive [16] reflex circuits can also be affected by an UMN syndrome and can contribute to 
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similar positive features (clonus, flexor spasms, clasp-knife phenomenon, static tonic stretch reflex 
[11, 17]). 
In 2003, the North American Task Force for Childhood Motor Disorders suggested that spasticity 
should be redefined as: “a velocity dependent increase in hypertonia with a catch when a threshold 
is exceeded” [5]. Although hypertonia is a common clinical term, the inability of clinical scales to 
differentiate between the neural and non-neural components of increased resistance, has led to the 
terms ‘spasticity’ and ‘hypertonia’ often being used interchangeably [18]. 
Outside a research setting, it is often impossible to isolate spasticity. Therefore, in clinical 
settings, different features are commonly combined and spasticity is referred to in a broader sense. 
In 2005, a European Thematic Network to Develop Standardized Measures of Spasticity (the SPASM 
consortium) suggested that the definition of spasticity should reflect a more clinical reality, and 
therefore broadened its definition. They defined spasticity as: “disordered sensory-motor control, 
resulting from an upper motor neuron lesion, presenting as intermittent or sustained involuntary 
activation of muscles” [19]. 
Both the previously mentioned narrow definitions, and the latter wider approach, have their 
disadvantages. When translating research findings to the clinic, the narrow definition results in a 
compromise on internal validity due the inability to isolate spasticity. On the other hand, a broad 
definition hinders the development of targeted treatments. Understanding the underlying 
pathophysiology can help to create a distinction between spasticity and the other positive features. 
Rather than compromising and broadening the definition, efforts should be directed at effectively 
isolating and measuring the phenomenon in a clinical setting. 
Another reason for the lack of agreement and on-going debate surrounding the definition of 
spasticity, is the emerging evidence that spasticity is manifested differently in an active versus 
passive muscle [20]. With the exception of the definition by the SPASM consortium, spasticity has 
always been described by the levels of hyperreflexia or hypertonia when the muscle is at rest. Since 
testing muscle tone during active movement is technically very challenging, these definitions are, in 
part, a reflection of feasibility. 
 
Pathophysiology of spasticity  
Spasticity is not caused by a single mechanism, but rather by intricate changes along different 
interdependent pathways [2]. Given the complexity involved in regulating normal muscle tone, an 
UMN lesion can cause spasticity via many different pathways (Figure 2). Additionally, the 
mechanisms are dependent on etiology, location and timing of the UMN lesion [21, 22].  
The pathophysiology of spasticity has mostly been investigated through animal models and adult 
pathologies [2, 15]. In general, loss of typical control occurs due to deregulation of the motor 
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pathways (mainly the corticospinal, reticulospinal, and the vestibulospinal tracts) running from the 
cerebral cortex and brain stem to the spinal cord [23]. Spasticity is not evident in lesions that affect 
only the corticospinal tract in the medullary pyramids or spinal cord [11]. Instead, damage to tracts 
that interact with the corticospinal tract is thought to contribute to spasticity. For example, damage 
along the reticulospinal tract decreases its inhibitory influence, resulting in increased muscle tone 
[15]. Loss of vestibulospinal tract excitation by the cortex is thought to cause decreased firing of the 
motor neurons, resulting in decreased extensor tone and thus a flexed posture. Other descending 
tracts thought to affect the regulation of stretch reflexes are the rubrospinal tract and the 
coerulospinal tract [11]. Further adaptations in the spinal networks as a result of the primary lesion 
are also thought to contribute to spasticity [15]. The main inhibitory spinal mechanisms thought to 
be involved in spasticity include reciprocal inhibition [23] and homosynaptic depression (also 
referred to as post-activation depression) [15]. While studies by Nielsen et al. (1995) demonstrated 
that decreased presynaptic inhibition played a role in spasticity in people with multiple sclerosis and 
spinal cord injury [21], in spasticity due to stroke, it seems not to be a systematic contributor [22, 
24]. Recurrent Renshaw cell inhibition and Ib inhibition (Figure 2), are additionally thought to be 
decreased in muscles with spasticity [11]. The main excitatory mechanisms found to be related to 
spasticity in chronic spinal cord injury [25] and in persons post-stroke [26] are plateau potentials [27] 
and enhanced cutaneous reflexes [15]. There is limited evidence of increased fusimotor drive [23]. 
Lastly, spasticity may also be aggravated by changes in the mechanical properties of muscles [28, 29], 
although little experimental evidence is present [27]. 
Unlike the pathology in adults whose motor system is developed at the time of injury, spasticity 
in children who suffer from an early brain abnormality is affected by reorganization of supraspinal 
input and impaired motor maturation. How the pathophysiology of spasticity is affected by 
maturation is an area of research which remains in its infancy of investigation. 
 
Quantitative measurement of spasticity 
 
In the last years, progress has been made to translate objective, instrumented spasticity 
measurement systems to clinical practice [6, 30–32]. These systems may still fall short of being able 
to distinguish between the different pathophysiological mechanisms of spasticity, but they have been 
shown to be more reliable and valid than the subjective clinical scales currently being used in most 
clinical settings [6, 33–38]. The most thorough set of reviews on spasticity assessments were carried 
out by the SPASM consortium in 2005 [39–41] and more recently, also by our own group [8]. 
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Figure 2. The major excitatory (red lines), inhibitory (blue lines), and processing (black lines) pathways involved 
in the reflex regulation contributing to normal trunk and limb muscle tone. Pathways numbered (1) and (2) 
travel first through interneurons before synapsing with alpha (α) motor neurons. GTO, Golgi Tendon Organ. 
*Some extrapyramidal tracts (not shown in this figure) also contribute to the maintenance of normal muscle 
tone and not all pathways shown are necessarily involved in increased stretch reflex due to spasticity. 
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Passive muscle assessments 
 
The neural component 
Approaches to assess spasticity when the muscle is at rest can be divided into clinical qualitative 
approaches and instrumented quantitative approaches. Quantitative approaches can further be 
divided into those methods that assess the neurophysiological response and those that assess the 
biomechanical response. Neurophysiological assessments help quantify elevated reflex responses. A 
commonly assessed example is the Hoffman reflex (H-reflex), elicited by low threshold electrical 
stimulation of a mixed peripheral nerve. Alternatively, a tendon tap will elicit the tendon reflex (T-
reflex), which follows a similar pathway to that of the H-reflex, but may also include the stretch-
reflex. Higher stimulation intensity of the mixed peripheral nerve results in the production of an M-
wave and the eventual disappearance of the H-reflex. Lower H- and T-reflex latencies, and higher 
reflex amplitudes are indicative of increased α-motorneuron excitability. The ratio of M-wave and 
reflex amplitudes (Hmax/Mmax and Tmax/Mmax) has been used as a measure of spasticity. However, 
there is much overlap in the values of these ratios between healthy and spastic muscles, reducing 
their diagnostic ability [39]. Eliciting Mmax also requires a supra-maximal stimulation, which is 
uncomfortable and therefore rarely used in children. 
Alternatively, systems based on evoking a stretch reflex can evaluate both the neurophysiological 
and biomechanical behavior of muscles, joints, and limb segments. For example, by making use of 
electromyography (EMG) and simultaneous recording of angular velocity and torques during various, 
well-defined conditions (such as passive oscillations, or ramp-and-hold stretches) when the muscle is 
at rest [39, 40]. In such methods, a distinction can be made between robotic designs where the 
passive limb is manipulated by a motor-driven system, and manual designs, where an examiner 
applies a muscle stretch. 
For eliciting the stretch reflex during passive movement, highly sophisticated, motor driven 
devices are the most accurate in standardizing and controlling joint trajectory and movement 
velocity. Modeling the behavior of muscles to such systems provides insight into different 
components of increased resistance to passive motion [42, 43]. However, these methods are 
impractical for clinical use, especially in pediatric populations [41]. Alternatively, several manually 
controlled methods that integrate signals have also been developed [6, 30, 44–46]. These methods 
highly resemble the clinical assessment scales, but additionally collect quantitative data using 
synchronized instruments. Since test performance will influence any collected signal, such tests 
require strict standardization. Additionally, thorough investigation of the psychometric properties of 
outcome parameters is essential prior to any clinical application. We recently reviewed the available 
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manually driven instrumented spasticity assessments and found that to date, there is a paucity in 
methods that have been validated for use in children with CP [8]. 
Therefore, in a number of recent studies, we have explored the clinical relevance of several 
quantified parameters collected with a manually driven Instrumented Spasticity Assessment (ISA), 
developed for the lower-limb muscles of children with CP [30, 34, 47–50]. ISA involves the 
simultaneous collections of EMG, velocity, and torque signals during ramp-and-hold passive muscle 
stretches at different velocities. The extracted parameters are compared between stretch velocities 
and include: the amount of hyper-activation (average root mean square-EMG) [30, 48], the degree of 
hypersensitivity to activation (the spastic threshold) [49], the presence, location and severity of a 
spastic catch [47], the type of muscle activation pattern (phasic or tonic) [49], torque at a particular 
angle, and work (the integral of torque versus position) [48]. A similar application for the elbow 
flexors has been validated for children with CP [51]. 
Although a measurement method based on passive movement may also result in muscle 
activation by other cutaneous and proprioceptive reflex loops, the developed EMG parameters can 
be presumed to capture the electrophysiological responses evoked by velocity-dependent afferent 
input. As such, they reflect the definition of spasticity as offered by Lance [3]. The developed 
biomechanical parameters follow the same reasoning. They represent the velocity-dependent 
increase in the resistance to movement, and are validated by a simultaneously occurring gain in the 
EMG signal. However, the exact relationship between evoked EMG and force production is not 
straightforward. Torque-related biomechanical parameters collected during passive stretch have 
proved to be less sensitive to the construct of spasticity than the simultaneously collected EMG-
related parameters [30, 39, 44]. In the medial hamstring and gastroc-soleus, our studies showed less 
response to anti-spasticity medication, Botulinum Toxin-A (BTX), in the torque- compared to the 
EMG-related parameters [34, 48, 50]. These findings suggest that these torque-related parameters 
may not adequately capture the contribution of spasticity to hypertonia. To do this, a more 
sophisticated decomposition of the torque signal is required. 
Several torque decomposition models have been developed to better understand hypertonia [37, 
42, 52–54], although only few have been applied in CP [43, 55]. The most straight forward of these 
models describe only the behavior of the non-neural components of hypertonia, such as passive 
stiffness [56] and viscosity [57]. These non-neural components have been studied in both healthy and 
hemiplegic subjects and are well described by polynomial or exponential mathematical models [42, 
56]. More sophisticated mathematical algorithms have additionally modeled the neural contribution 
to the resistance measured during passive stretch [42, 43, 52]. De Gooijer van de Groep et al. 
reported that reflex-related torque in the plantarflexors of children with CP was almost six times 
higher, and tissue stiffness double, that of controls [43]. Contradictory findings were found by 
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Willerslev-Olsen et al. where the majority of assessed soleus muscles exhibited abnormal non-neural 
related stiffness, but in only a minority was reflex-related torque higher than that of controls [55]. 
These contradictions may be a reflection of different perturbation methods (six degree movements 
[43] vs. ramp-and-hold rotations over the entire range of motion [55]) and different torque 
decomposition models. Additionally, while de Gooijer van de Groep et al. included all three 
plantarflexors, Willerslev-Olsen. et al. analyzed only the soleus, which is not often treated for 
spasticity. Both articles reported a large variation in the ratio of neural and non-neural components 
in their sample, which emphasizes the need to individually define these components. 
Most decomposition models have only ever been validated on data collected with motor-driven 
systems in which the displacement and/or the force applied can be well controlled. More recently, 
our group has applied a simpler method to extract the neural component based on measurements 
from the manually controlled ISA [50]. A simple model that describes stiffness and viscosity in 
healthy muscle was approximated from the algorithms introduced by de Vlugt et al. (2010) [42]. This 
model was fitted to the torque-position data collected at the ankle during low velocity full range of 
motion manipulations. The model was then fitted to stretches in which a stretch reflex was evoked 
(high velocity stretches). The amount of deviation between the modeled and measured torque 
during these latter stretches represented the pathological neural component. This ‘deviation-
parameter’ was found to be repeatable between assessments and to distinguish between healthy 
and spastic muscle. Additionally, unlike the previously described torque-related parameters 
containing both neural and non-neural components, the deviation-parameter was found to decrease 
post-BTX [50]. 
This may be the first step towards breaking down the measured torque into a clinically-relevant 
representation of the contribution of spasticity to hypertonia. Unfortunately, this method could not 
be used to accurately estimate the amount of stiffness and viscosity nor to separate the properties of 
muscles from the properties of tendons (see discussion in [50]). To achieve this, a combination of 
muscle imaging and modeling work is required and is scope for further study. 
When quantifying the neural component, it is also important to consider that different muscles 
possess different activation patterns and different biomechanical properties. Consequently, the 
effect of spasticity on hypertonia will be muscle-specific. In a study carried out with ISA on several 
lower limb muscles in children with CP, we identified earlier stretch reflex thresholds and less 
velocity-dependent activation in the hamstrings and adductor muscles when compared to the 
gastrocnemius [58]. Similarly, in the upper limbs of persons post-stroke, Kamper et al. found earlier 
reflex thresholds and greater reflex responses in the finger flexors than in the elbow flexors [16]. 
Activation differences between muscles may be caused by differences in central and peripheral 
stretch reflex modulation and/or by the different morphological makeup of muscles. For example, 
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muscle force generation is influenced by muscle specific properties such as moment arm, cross 
sectional area, and pennation angle. Differences may also reflect the dependence of a reflex 
response on joint position prior to stretch [59]. The rectus femoris and gastrocnemius have been 
found to be less sensitive when stretched from initially longer lengths [60], whilst in the hamstrings, 
the opposite has been reported [17]. In bi-articular muscles, the position of both joints is important 
when considering length dependency [59]. Therefore, subject positioning and measurement setup 
are important considerations when assessing spasticity and will depend on which muscle is being 
assessed. 
 
The non-neural component 
In the classical understanding of the impairments in CP, it is generally thought that prolonged 
activation due to spasticity will cause fiber shortening which results in stiffer muscles [14]. Following 
this reasoning, spasticity can be regarded as the primary cause of hypertonia and hence, the primary 
target for treatment. Spastic muscles have indeed been found to be smaller in volume, cross 
sectional area, and muscle thickness compared to muscles of typically developing children [61]. 
However, contrary to the ‘spasticity-induced short-fiber mechanism’, studies have reported fewer, 
yet long sarcomeres in spastic muscle fibers [7]. A possible explanation may be that sarcomeres in 
the spastic muscle distend due to lack of growth of the muscle with bone [7]. The relationship of 
these changes with spasticity severity is uncertain [62]. 
Results from upper limb muscle biopsy studies indicate that the tensile modulus of spastic 
muscle cells is more than double that of muscle cells of control subjects [7]. In spastic hamstrings, 
increased passive stiffness is caused by increased amounts of collagen in the extracellular matrix of 
muscle fiber bundles [63]. Recent findings report that these changes already occur in children with 
CP younger than 3 years old [55, 64] and that growth velocity, rather than spasticity, plays a crucial 
role in these alterations [65]. In line with these findings, muscle stiffness has been reported to 
increase [66], whereas spasticity decreases with age [67]. Some studies using motor-driven devices 
have reported higher non-neural contributions than neural to the torque measured during passive 
ankle joint rotations in children with CP [55]. Literature thus suggests that the non-neural muscle 
stiffness is as, or possibly more, important than spasticity. 
Similar conclusions on the importance of the non-neural component in the gastroc-soleus have 
been derived from our own study in which the previously described work parameter significantly 
differed between spastic and healthy muscles, but was unaffected by BTX combined with about two 
weeks of casting [50]. While the indirect effect of BTX injections on muscle stiffness and viscosity is 
not fully understood, these insights may imply that on a group level, the non-neural component of 
hypertonia may not have been adequately managed. 
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Imaging of the behavior of muscles and tendons in vivo using ultrasound (US) can provide a 
means to quantify muscle morphology and assess passive muscle properties [68, 69]. Dynamic US 
involves the real-time capture and reconstruction of images during movement. By measuring joint 
torque and US during muscle-tendon lengthening, the amount of torque produced per given amount 
of tissue length can be used to create stress-strain curves [70]. The properties of these curves can 
provide an indication of stiffness and viscosity in muscles and tendons. Such applications would 
complement instrumented spasticity assessment providing the necessary information on non-neural 
components of hypertonia. 
 
Active muscle assessments 
The ultimate goal of hypertonia management in CP is to improve function, such as gait. Specific 
gait deviations such as early heel rise, knee flexion at initial contact, and stiff-knee gait have been 
attributed to spasticity [13]. It has also been suggested that muscle stiffness may arise as a 
compensation for the lack of neural control [20, 71]. However, it is important to realize that gait, and 
especially pathological gait, is multifaceted. Other impairments in CP, such as muscle weakness, 
involuntary co-activation, lack of muscle control and balance problems, as well as compensatory 
mechanisms, will interplay with hypertonia and have an effect on gait deviations [20]. Consequently, 
these additional factors make ascertaining the isolated impact of hypertonia on movement 
abnormalities very challenging. For example, co-activation occurs when there is simultaneous motor 
drive to both agonist and antagonist. Involuntary co-activation is necessary for normal movement, 
although when excessive and inappropriate, it can also hinder it. However, co-activation is different 
from activation of the stretch reflex in a lengthened antagonist due to agonist contraction [11]. 
During activity, when both co-activation and stretch reflex activation will contribute to hypertonia, 
the distinction between different causes is difficult to make. 
Optimal reflex activation is important in adjusting joint impedance as required for movement 
[20]. During activity, lack of modulation of H- and stretch reflexes may be indicative of spasticity. For 
example, when activated, muscles with spasticity have shown less H-reflex modulation than muscles 
of healthy controls [72]. Similarly, short-latency reflexes of the soleus muscles are exaggerated in 
adults [1] and children [71] with spasticity, while long latency reflexes are decreased. Although reflex 
related impairments can be expected to impede function in muscles with spasticity, their exact 
contribution to muscle hypertonia is difficult to assess.  
Instead, several research groups have explored the relationship between muscle lengthening 
velocity and EMG during gait. Crenna (1998) was the first to describe a pathological relationship 
between muscle lengthening velocity and EMG during the stance phase in children with CP. He 
termed this pathological relationship ‘dynamic spasticity’ [73]. In the hamstrings, he observed that 
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dynamic spasticity was manifested by a low muscle activation threshold at mid- and terminal swing. 
In the soleus, it was manifested by both a lowered threshold and increased activation during initial 
stance. In subsequent studies, Lamontagne et al. (2001) confirmed that increased activation in the 
gastrocnemius during stance and swing in adults post stroke were coincident with peak muscle 
lengthening velocity [74]. Van der Krogt et al. (2010) found similar results in children with CP, but for 
the gastrocnemius during terminal swing [75]. However, in the latter study, contrary to their 
expectations, dynamic spasticity at high walking velocity was masked by the activation required to 
walk faster [75]. Similar results were found in a study carried out by our own research group, where 
comparable strategies to increase walking speed were employed by children with CP and typically 
developing children [76]. In line with this, we have recently found that reduced muscle lengthening 
velocity in the hamstrings during swing was associated with higher muscle activity during swing at a 
self-selected walking speed, but that these associations were no longer present at a faster walking 
condition [77]. Passive stiffness of the gastroc-soleus and weakness of the tibialis anterior are 
probably better predictors of limited dorsiflexion in terminal swing than spasticity [71]. Limited 
hamstrings lengthening in swing may also be explained by stiffness [78], lack of balance, and the 
activation necessary to decelerate knee extension [79]. 
To be able to continue to analyze and understand the impact of hypertonia on gait, more 
information is needed on how muscles and tendons lengthen in passive conditions and during gait. 
Longer than normal Achilles tendons have been reported in children with spastic CP [80]. Van der 
Krogt et al. (2009) found similar muscle-tendon lengthening patterns during gait in contractured and 
non-contractured muscles [81]. These findings may imply that contractured muscles, or muscles with 
altered mechanical properties, lengthen by means of a highly extensible tendon and that muscle 
stretch reflexes play only a minor role during walking. Ideally, to correctly investigate this, dynamic 
US that tracks muscle and tendon lengthening during gait should be combined with measurements of 
EMG. 
 
Future clinical implications 
In a heterogeneous condition such as CP, a personalized approach to treatment is warranted. 
Objective instrumented assessments that provide the treating clinician with an individualized muscle 
specific hypertonia profile can be beneficial in fine-tuning a child’s treatment. If research confirms 
that BTX primarily targets neural components whereas casting primarily influences the non-neural 
muscle properties, the next step would be to assess the effect of fine-tuning the combination of 
these two treatment modalities to a muscles’ hypertonia profile. For example, if a muscle possesses a 
larger non-neural component, a smaller dosage of BTX and a longer casting period may be indicated. 
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If lower BTX dosages achieve the same effect when combined with the correct period of casting, this 
may also be economically more advantageous.  
Another important clinical application is prediction of treatment outcome. The observed 
variability of impairments and their response to treatment can be investigated in terms of diagnosis 
(uni- vs. bilateral CP), age, sex, functional level, etiology (malformations, periventricular 
leukomalacia, cortico-subcortical lesions), and timing of a brain lesion (pre- or post-natal). Initial 
findings seem to suggest that spasticity parameters collected in the hamstrings at baseline can be 
used to predict treatment outcome with BTX [34]. Furthermore, different lower limb muscles in 
children with CP have shown to have different EMG patterns during passive stretch. In a study of 54 
children with CP, passive gastrocnemius and rectus femoris stretches were shown to evoke highly 
velocity-dependent phasic muscle activity. On the other hand, longer duration tonic activation which 
began at lower stretch velocities was found in the hamstrings and adductors [49]. More research is 
required to understand the etiology behind these differences and test the hypothesis that spasticity 
treatment should be muscle- and possibly also pattern-specific.  
In addition to BTX, other tone reduction treatments such as intrathecal baclofen and selective 
dorsal rhizotomy (SDR) can be fine-tuned to achieve optimal results. Studying and comparing the 
outcomes of the different spasticity treatments on each component of hypertonia can improve our 
understanding of the working mechanisms of the treatment modalities in normalizing the motor 
response. Longitudinal studies (in children and adults) may help to deduce the time course 
development of the different components of hypertonia. In turn, this will help define optimal 
therapeutic intervention with increasing age.  
Importantly, more investigations are required to improve our understanding of the 
pathophysiology of hypertonia, including other primary impairments that contribute to it. Most 
studies attempting to quantify spasticity exclude subjects with dystonia. Unlike spasticity, dystonia is 
not dependent on afferent input and is not velocity dependent [11]. Therefore, the presence of 
dystonia can be distinguished from spasticity as it is already detectable in certain postures. 
Nevertheless, dystonia is affected by increasing muscle length [82]. Consequently, when spasticity 
and dystonia co-exist, quantifying their separate contributions to hypertonia is a challenge. 
Finally, a comprehensive platform for assessment should eventually consider all aspects, from 
muscle behavior during well-controlled passive stretches to muscle behavior during active motion. 
Therefore, clinical findings on the components of hypertonia assessed in an analytical manner should 
always be compared to measurements of activity and function. Such insight will undoubtedly help 
direct treatment towards its optimum goal which is to maximize a child’s functional potential. 
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From the above evidence it can be concluded that hypertonia should be regarded as 
multifactorial and that equating all resistance to passive motion with spasticity is erroneous. 
Spasticity is only a contributor to this resistance, and the extent of the contribution probably differs 
among muscles and individuals. In this regard, the preeminent goal should be to adequately analyze 
the components of hypertonia. Recent developments in instrumented spasticity assessment provide 
a strong methodological basis on which to develop more rigorous differentiation of hypertonia into 
its constituents. More clinically-based research is required to validate and improve our treatment 
modalities and to understand the effect of hypertonia on movement. 
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